Sen-Jam Pharmaceutical's SJP-001 Receives Ethics Approval for Clinical Trial in Australia

• Sen-Jam Pharmaceutical's SJP-001, an over-the-counter therapeutic, has received ethics approval for a clinical trial in Australia.
• The trial, conducted by Nucleus Network and supported by Novotech, will assess SJP-001's efficacy and safety in modulating inflammation and improving metabolic outcomes.
• SJP-001 targets metabolic health and aims to provide relief from overindulgence in food and drink by affecting inflammatory pathways.
• This approval marks a significant step for SJP-001 in becoming a globally accessible, non-immunosuppressive solution for inflammation.

Sen-Jam Pharmaceutical has announced that its flagship product, SJP-001, has received ethics approval to begin clinical trials in Australia. The trial, conducted in partnership with Nucleus Network and Novotech, will evaluate the therapeutic's safety and efficacy in addressing inflammation and improving metabolic health, particularly in the context of dietary overindulgence.

The SJP-001 trial is designed to assess the product's ability to modulate inflammation and improve metabolic outcomes. Sen-Jam Pharmaceutical is focused on creating accessible solutions that deliver meaningful health improvements on a global scale. The company's leadership is currently in San Francisco for the JPMorgan Healthcare Conference to discuss their vision, pipeline, and partnership opportunities.

Collaboration and Expertise

Jim Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical, stated that the ethics approval in Australia is a pivotal step for SJP-001 and their mission to bring accessible, non-immunosuppressive solutions to global markets. Barry Murphy, CCO of Novotech, added that Novotech's experience in the Asia-Pacific region positions them to drive the success of SJP-001's development. Teena Pisarev, CEO of Nucleus Network, emphasized the importance of precision-targeted inflammation therapeutics and their commitment to supporting therapies like SJP-001.

About SJP-001

SJP-001 is an over-the-counter therapeutic designed to target metabolic health and provide relief from the effects of overindulgence in food and drink. It aims to modulate inflammatory pathways to support long-term metabolic health. Sen-Jam Pharmaceutical is dedicated to revolutionizing inflammation care with scalable, accessible solutions that deliver meaningful health improvements globally.

Sen-Jam's Focus

Sen-Jam Pharmaceutical is focused on addressing chronic inflammation and metabolic disorders, including obesity, through its "Pleiotropic Anti-Inflammatory Remedies" (PAIR) technology. These remedies target inflammation at its source without suppressing the immune response, aiming to mitigate systemic risks associated with chronic conditions.